| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BGLF2 |
| Uniprot No | P0CK53 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-336aa |
| 氨基酸序列 | MASAANSSREQLRKFLNKECLWVLSDASTPQMKVYTATTAVSAVYVPQIAGPPKTYMNVTLIVLKPKKKPTYVTVYINGTLATVARPEVLFTKAVQGPHSLTLMYFGVFSDAVGEAVPVEIRGNPVVTCTDLTTAHVFTTSTAVKTVEELQDITPSEIIPLGRGGAWYAEGALYMFFVNMDMLMCCPNMPTFPSLTHFINLLTRCDNGECVTCYGAGAHVNILRGWTEDDSPGTSGTCPCLLPCTALNNDYVPITGHRALLGLMFKPEDAPFVVGLRFNPPKMHPDMSRVLQGVLANGKEVPCTAQPWTLLRFSDLYSRAMLYNCQVLKRQVLHSY |
| 预测分子量 | 44.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BGLF2重组蛋白的示例性参考文献(内容为假设性概括，实际文献需通过学术数据库验证)：
---
1. **文献名称**：*Characterization of Epstein-Barr Virus BGLF2 Protein in Viral Assembly*
**作者**：Sato, R., Yokoyama, H. et al.
**摘要**：本研究利用重组BGLF2蛋白分析了其在EB病毒粒子组装中的功能，发现BGLF2与病毒核衣壳蛋白相互作用，促进病毒DNA包装和成熟颗粒释放。实验通过体外表达纯化BGLF2.并利用免疫共沉淀验证其与BcRF1的互作。
2. **文献名称**：*Recombinant BGLF2 Kinase Activity and Its Role in Immune Evasion*
**作者**：Liu, Y., Wang, T. et al.
**摘要**：作者在大肠杆菌中表达并纯化重组BGLF2蛋白，证实其具有丝氨酸/苏氨酸激酶活性，可磷酸化宿主细胞STAT1蛋白，抑制干扰素信号通路，从而帮助EB病毒逃逸宿主先天免疫应答。
3. **文献名称**：*BGLF2 Modulates Host Cell Cycle via Interaction with Cyclin-Dependent Kinases*
**作者**：Alawi, M., Müller, C. et al.
**摘要**：通过重组BGLF2蛋白的体外结合实验，研究发现其与宿主CDK2结合并阻滞细胞周期于G1/S期，为EB病毒在潜伏感染中维持宿主细胞稳态提供了机制证据。
4. **文献名称**：*Structural and Functional Analysis of BGLF2 in Viral Tegument Formation*
**作者**：Chen, J., Zhang, L. et al.
**摘要**：利用晶体学解析重组BGLF2蛋白的三维结构，揭示其C端结构域介导与病毒tegument蛋白BPLF1的相互作用，对病毒粒子在宿主细胞内的运输至关重要。
---
**注意**：以上为假设性文献示例，实际研究需检索PubMed、Google Scholar等平台，结合关键词“BGLF2 recombinant protein”“Epstein-Barr virus BGLF2”等获取真实文献。
BGLF2 is a regulatory protein encoded by the Epstein-Barr virus (EBV), a gammaherpesvirus associated with various malignancies, including Burkitt’s lymphoma, nasopharyngeal carcinoma, and lymphoproliferative disorders. As a late gene product expressed during the lytic phase of the EBV life cycle, BGLF2 plays a multifaceted role in viral replication and host immune evasion. It is classified as a tegument protein, which are critical for virion assembly and modulation of host cell signaling pathways. Studies suggest BGLF2 interacts with cellular proteins to manipulate host defenses, such as inhibiting interferon signaling or disrupting antiviral apoptosis, thereby facilitating viral persistence.
Recombinant BGLF2 protein is engineered for functional and structural studies to elucidate its mechanisms in EBV pathogenesis. Produced via heterologous expression systems (e.g., E. coli or mammalian cells), the recombinant protein retains antigenic or enzymatic properties for in vitro assays. Researchers utilize it to investigate protein-protein interactions, immune responses, and its role in viral tegument formation. Additionally, recombinant BGLF2 serves as a tool for developing diagnostic reagents, such as ELISA-based antibody detection in EBV-associated diseases, or screening antiviral compounds targeting its functional domains.
Despite progress, BGLF2’s precise molecular functions remain incompletely understood. Its ability to modulate host kinases and immune checkpoints highlights its therapeutic potential. However, challenges include its transient expression during lytic replication and overlapping functions with other EBV proteins. Ongoing research aims to clarify its contributions to viral oncogenesis and immune evasion, which could inform novel antiviral strategies or biomarkers for EBV-related cancers.
×
